CXCR2 and neoplasm: Preclinical studies with CD70-CXCR1 or CD70-CXCR2 CAR-T cells have revealed that the T cells were markedly enhanced to migrate and survive in intra-tumoral region, such as GBM, resulting in complete tumor regressions.